GLP-1 Receptor Agonists Surge in Pediatric Type 2 Diabetes Treatment
A new study published in *Pediatrics* reveals a significant increase in the dispensing of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for youth with type 2 diabetes (T2D) between 2020 and 2023. Using commercial and Medicaid claims data, researchers found the annual prevalence of GLP-1RA dispensing rose from 10.9% to 35.6%. While this marks a substantial shift in pharmacotherapeutic strategy, these agents are still dispensed less frequently than both long- and short-acting insulin. The research also uncovered a disparity in the specific GLP-1RAs used: Medicaid-insured youth were significantly less likely to receive semaglutide and more likely to receive dulaglutide, exenatide, or liraglutide compared to their commercially insured peers, highlighting potential access or formulary differences.
Why it might matter to you: This real-world data on GLP-1RA utilization trends is critical for pharmacologists and clinicians monitoring the post-market adoption and comparative effectiveness of novel drug classes. The observed insurance-based disparity in agent selection underscores the complex interplay between pharmacoeconomics, formulary design, and personalized medicine in pediatric populations, a key consideration for drug development and health policy strategies.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
